292 related articles for article (PubMed ID: 33811122)
1. Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies.
Aldea M; Andre F; Marabelle A; Dogan S; Barlesi F; Soria JC
Cancer Discov; 2021 Apr; 11(4):874-899. PubMed ID: 33811122
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms and strategies to overcome immunotherapy resistance in hepatobiliary malignancies.
Xiong J; Wang QQ
Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):430-439. PubMed ID: 35907687
[TBL] [Abstract][Full Text] [Related]
3. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
4. Impact of cancer metabolism on therapy resistance - Clinical implications.
Gonçalves AC; Richiardone E; Jorge J; Polónia B; Xavier CPR; Salaroglio IC; Riganti C; Vasconcelos MH; Corbet C; Sarmento-Ribeiro AB
Drug Resist Updat; 2021 Dec; 59():100797. PubMed ID: 34955385
[TBL] [Abstract][Full Text] [Related]
5. Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy.
Wu D; Wang DC; Cheng Y; Qian M; Zhang M; Shen Q; Wang X
Semin Cancer Biol; 2017 Feb; 42():13-19. PubMed ID: 27840278
[TBL] [Abstract][Full Text] [Related]
6. The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine.
Li X; Li M; Huang M; Lin Q; Fang Q; Liu J; Chen X; Liu L; Zhan X; Shan H; Lu D; Li Q; Li Z; Zhu X
Biomed Pharmacother; 2022 Jun; 150():113064. PubMed ID: 35658234
[TBL] [Abstract][Full Text] [Related]
7. Tackling the tumor microenvironment: what challenge does it pose to anticancer therapies?
Chen F; Qi X; Qian M; Dai Y; Sun Y
Protein Cell; 2014 Nov; 5(11):816-26. PubMed ID: 25185441
[TBL] [Abstract][Full Text] [Related]
8. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
9. Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine.
Bashraheel SS; Domling A; Goda SK
Biomed Pharmacother; 2020 May; 125():110009. PubMed ID: 32106381
[TBL] [Abstract][Full Text] [Related]
10. Macrophages: Key orchestrators of a tumor microenvironment defined by therapeutic resistance.
Long KB; Collier AI; Beatty GL
Mol Immunol; 2019 Jun; 110():3-12. PubMed ID: 29273393
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives.
Pellino A; Riello E; Nappo F; Brignola S; Murgioni S; Djaballah SA; Lonardi S; Zagonel V; Rugge M; Loupakis F; Fassan M
World J Gastroenterol; 2019 Oct; 25(38):5773-5788. PubMed ID: 31636471
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy in cancer.
Tsimberidou AM
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1113-32. PubMed ID: 26391154
[TBL] [Abstract][Full Text] [Related]
14. The multi-factorial nature of clinical multidrug resistance in cancer.
Assaraf YG; Brozovic A; Gonçalves AC; Jurkovicova D; Linē A; Machuqueiro M; Saponara S; Sarmento-Ribeiro AB; Xavier CPR; Vasconcelos MH
Drug Resist Updat; 2019 Sep; 46():100645. PubMed ID: 31585396
[TBL] [Abstract][Full Text] [Related]
15. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.
Dzobo K
OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic cancer vaccines: From initial findings to prospects.
Song Q; Zhang CD; Wu XH
Immunol Lett; 2018 Apr; 196():11-21. PubMed ID: 29407608
[TBL] [Abstract][Full Text] [Related]
17. Circumventing cancer drug resistance in the era of personalized medicine.
Garraway LA; Jänne PA
Cancer Discov; 2012 Mar; 2(3):214-26. PubMed ID: 22585993
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in glioblastoma: emerging options in precision medicine.
Hodges TR; Ferguson SD; Heimberger AB
CNS Oncol; 2016 Jul; 5(3):175-86. PubMed ID: 27225028
[TBL] [Abstract][Full Text] [Related]
19. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
20. Shared neoantigens: ideal targets for off-the-shelf cancer immunotherapy.
Zhao W; Wu J; Chen S; Zhou Z
Pharmacogenomics; 2020 Jun; 21(9):637-645. PubMed ID: 32423288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
